
Lilly to Present Phase 3 EMBER-3 Study Results for Imlunestrant at San Antonio Breast Cancer Symposium
Eli Lilly and Company (NYSE: LLY) has announced that data from the Phase 3 EMBER-3 trial of imlunestrant, an oral selective estrogen receptor degrader (SERD), will be presented for the…













